miR-aculous new avenues for cancer immunotherapy is a research paper published in Frontiers in Immunology (2022). On theSindex it has a DataRank of 0. It has been cited 12 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: F30 CA260977
National Institutes of Health
Grant: 1F30CA260977, Al138945, 1F31CA261096
NCI NIH HHS
Grant: F31 CA261096
National Institutes of Health
Grant: 5F31CA261096-03
Melanoma NAMPT mediates resistance to the anti-proliferative effects of Interferons (IFNs) and IFN based immunotherapies such as STING Agonists
National Institutes of Health
Grant: 1F30CA260977-01
T cell expressed miR-155 promotes antitumor immunity and immune checkpoint blockade responses in colon cancer through repression of Ship1
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals